Effect of Solvent on Stereoselectivity in Pd/C (Type 39K)-Catalyzed Hydrogenation of Methyl 3-Oxo-4-Aza-5-Androstene-17-Carboxylate, a Key Intermediate for Finasteride and Dutasteride

This review provides an up-to-date analysis of the efficacy and safety of five-alpha reductase inhibitors, specifically finasteride and dutasteride, for treating benign prostatic hyperplasia and male androgenetic alopecia, highlighting their FDA approval history and current use.

In this study, dutasteride, but not finasteride, reduced high-grade PIN lesions more effectively in C57xFVB TRAMP mice, although both drugs increased the incidence of poorly differentiated prostate cancer.

This study optimized the reaction conditions for the stereoselective hydrogenation of a compound used in manufacturing finasteride and dutasteride, improving the selectivity for the desired isomer.